Share this article
Share this article
SEATTLE, April 14, 2021 /PRNewswire/ Magnolia Medical Technologies, Inc. recently launched a new multi-media advertising campaign to promote the benefits of the Steripath
® Initial Specimen Diversion Device
® (ISDD
®) platform.
Built around the theme Diverted , the campaign underscores the critical need for the use of Magnolia s ISDD, which diverts the initial 1.5-2.0 mL of blood while maintaining a vein-to-bottle closed system which reduces blood culture contamination rates and false-positive central line-associated bloodstream infections (CLABSI) to improve patient outcomes.
(PRNewsfoto/Magnolia Medical Technologies) Diverted embraces bold new creative assets to support a multichannel media campaign that engages healthcare leadership as well as stakeholders within emergency departments, infection prevention, quality, laboratory and nursing. The creative is designed to educate these audiences on the clinical and economic impli
Magnolia Medical Launches New Diverted Multi-Media Advertising Campaign to Educate Healthcare Providers on Benefits of Steripath®
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Magnolia Medical Launches New Diverted Multi-Media Advertising Campaign to Educate Healthcare Providers on Benefits of Steripath®
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
®, the only FDA-cleared device platform indicated to reduce blood culture contamination
1 – today announced that unprecedented Steripath clinical study results were presented to the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB).
Lucy S. Tompkins, MD, Ph.D., a professor and infectious diseases, microbiology and epidemiology expert at Stanford Health Care, presented Steripath
® Gen2 Initial Specimen Diversion Device
® (ISDD
®) phase-one study results at the PACCARB meeting in Washington, DC demonstrating unmatched reductions to blood culture contamination and false-positive central line-associated bloodstream infection (CLABSI) rates. What was even more clinically significant is that a 0.0% contamination rate and 0.0% false-positive CLABSI rate were maintained across over 11,000 blood cultures when Steripath was used throughout the course of the 10-month total trial period, continued Dr. Tompkins